Construction of a predictive model for gemcitabine combined with cisplatin resistance in intrahepatic cholangiocarcinoma based on multidimensional inflammatory indices

The predictive model based on CA19-9, ALB, and SII can identify early the risk of CisGem resistance in iCCA patients, characterized by high statistical efficacy, low testing costs, and strong clinical applicability, suggesting potential for clinical application pending prospective validation. This model serves as a clinical risk stratification tool to assist in identifying high-risk iCCA patients requiring treatment adjustment, particularly suitable for primary and resource-limited healthcare settings with strong potential for widespread implementation. Multi-center external validation remains the necessary next step.